Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

NCT04580745
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MORF-057, Placebo for MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 15, 2026, 10:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

NCT07219030
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
65 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Cypress, California • Maitland, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

NCT00796965
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 15, 2026, 10:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

NCT04403763
View directory record Official record
Conditions
Presbyopia
Interventions
AGN-241622, Vehicle
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Inglewood, California • Los Angeles, California • Mission Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

NCT03803644
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 15, 2026, 10:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous ZMA001 in Healthy Subjects

NCT05967299
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy Subjects

NCT03627845
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PHP-303, Placebo
Drug · Other
Lead sponsor
pH Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

NCT05056246
View directory record Official record
Conditions
Healthy Participants
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

NCT05031624
View directory record Official record
Conditions
Healthy Subjects
Interventions
CDX-0159, Normal saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

NCT01471717
View directory record Official record
Conditions
Healthy
Interventions
INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Study of Bemnifosbuvir in Healthy Japanese Subjects

NCT05905497
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability

NCT03329014
View directory record Official record
Conditions
Procedural Sedation
Interventions
Remimazolam, Placebo
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020

NCT05045833
View directory record Official record
Conditions
Enteritis Caused by Radiation
Interventions
SYN-020 Delayed Release Capsule
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

NCT02399449
View directory record Official record
Conditions
Anemia
Interventions
Brand sodium ferric gluconate, Generic sodium ferric gluconate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00959426
View directory record Official record
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

NCT02004678
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-1150b, Placebo
Drug · Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

NCT02124278
View directory record Official record
Conditions
Healthy
Interventions
PUL-042 Inhalation Solution
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 15, 2026, 10:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

NCT01981694
View directory record Official record
Conditions
Healthy
Interventions
PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

NCT02045849
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

NCT02568306
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0165-1562, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 15, 2026, 10:08 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

NCT07856706
View directory record Official record
Conditions
Healthy Subjects
Interventions
ABBV-7828, Placebo for ABBV-7828
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

NCT01350921
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Ticagrelor, Venlaflaxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 15, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

NCT04472832
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo for Treatment A, Mitapivat 100 mg, Placebo for Treatment B, Mitapivat 300 mg, Placebo for Treatment C
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 15, 2026, 10:08 PM EDT